MetaCap

Phathom Pharmaceuticals Inc. (PHAT)

NASDAQ: PHATHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.66-0.42 (-8.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PHAT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$378.82M
EPS (TTM)
-$1.01
52-week range
4.62 – 18.31
Day range
4.62 – 5.15
Volume / Avg
1.33M / 1.45M
Beta
—

52-week range

$4.62$18.31

PHAT stock today

Phathom Pharmaceuticals (PHAT) closed at $4.66 on Nov 20, down 8.27% (-$0.42), versus the S&P 500's 3.70% decline. Shares are 74.5% below their 52-week high of $18.31, set on Dec 23, 2025 and 1.0% above the 52-week low of $4.62, near the bottom of the past year's range. PHAT is down 71.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.9%.

Phathom Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Phathom Pharmaceuticals

Company profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Steven L. Basta M.B.A.
Headquarters
Florham Park, NJ
Employees
371
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Phathom Pharmaceuticals generated $175.1 million in revenue, up 216.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Phathom Pharmaceuticals reported a net loss of $221.2 million, compared with a loss of $334.3 million a year earlier. Gross margin was 87.1% (up from 85.6%) and operating margin -91.4%.

Phathom Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$175.11M$55.25M$682.00K$0—
Growth+216.93%+8001.47%———
Net income$-221.25M$-334.33M$-201.59M$-197.72M$-143.88M
EPS (diluted)$-3.03$-5.29$-3.93$-5.05$-3.89

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$19.65+321.67%

  • Strong buy 2
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $7.50High $29.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.16 vs $-0.01
Surprise
-1500.00%

PHAT news

All PHAT news

Phathom Pharmaceuticals peers

Health Care sector
PHAT peer companies
CompanyPrice% ChgMarket capCompare
IRDOpus Genetics Inc.3.99-2.21%$385.65Mvs PHAT
AVTXAvalo Therapeutics Inc.6.76+0.15%$390.88Mvs PHAT
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs PHAT
OCSOculis Holding AG7.06-5.11%$393.35Mvs PHAT
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs PHAT
PEPGPepGen Inc.3.78-3.82%$356.31Mvs PHAT
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs PHAT
CTNMContineum Therapeutics Inc. Class A8.68-3.98%$340.83Mvs PHAT

Indexes, lists and sector

Phathom Pharmaceuticals stock FAQ

What is Phathom Pharmaceuticals's stock price today?

PHAT last traded at $4.66 as of Nov 20, 4:00 PM EST, down 8.27% on the day. Prices are delayed at least 15 minutes.

Who is Phathom Pharmaceuticals's CEO?

Mr. Steven L. Basta M.B.A. is the chief executive officer of Phathom Pharmaceuticals Inc., which has about 371 employees.

What is the PHAT 52-week high?

The 52-week high for PHAT is $18.31 and the 52-week low is $4.62. The stock is currently 74.5% below its high.

Compare PHAT